Joshua Woolley, MD, PhD

Title(s)Associate Professor, Psychiatry
SchoolSchool of Medicine
Address675 18th Street, #001
San Francisco CA 94107
Phone415-221-4810 ext. 4117
PronounsHe/Him/His
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences


    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Residency 2011School of Medicine
    University of California, San FranciscoM.D.2007 School of Medicine
    University of California, San FranciscoPh.D.2005 Graduate Division (Neuroscience)
    Brown University, Providence, RIBachelor of Science1999Biology and Philosophy

    Collapse Overview 
    Collapse Overview
    Dr. Josh Woolley is an Associate Professor in Residence in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF) as well as a staff psychiatrist in Mental Health at the San Francisco Veterans Affairs Medical Center (SFVAMC). He is Board Certified in Psychiatry by the American Board of Psychiatry and Neurology. He is the Director of the Translational Psychedelic Research (TrPR) Program at UCSF, which brings together scientists and care providers across disciplines to understand the efficacy, safety, and therapeutic mechanisms of psychedelic compounds including psilocybin, MDMA, and ketamine, for multiple neuropsychiatric disorders.

    In addition to his work as a researcher, Dr. Woolley is also a dedicated mentor, clinician, and educator who enjoys training the next generation of clinicians and scientists. Over the course of his career, Dr. Woolley has mentored over 30 postdoctoral fellows and 8 junior faculty members. He is the Associate Director of the Psychosis Clinic at the SFVA where he supervises and trains medical students, psychiatry residents, and clinical and research fellows. He has also served as the Co-Director of the first-year medical school psychiatry course Brain Mind and Behavior, and has been given several awards for his dedication to teaching.

    Dr. Woolley has received numerous intramural and extramural awards including the NARSAD Young Investigator Award from the Brain & Behavior Research Foundation, the Young Investigator Award, as well as travel awards from the California Society for Addiction Medicine, the American Society of Clinical Psychopharmacology, and the American Academy of Addiction Psychiatry. He is an Associate Member of the American College of Neuropsychopharmacology. His work is supported by the Department of Veteran Affairs as well as the Department of Defense, philanthropy, and industry. He has published his work widely in high-impact journals including JAMA, Nature Neuroscience, Schizophrenia Bulletin, Biological Psychiatry, and American Journal of Psychiatry, among others.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A systematic review of participant diversity in psychedelic-assisted psychotherapy trials. Psychiatry Res. 2025 Jan 10; 345:116359. Haft SL, Downey AE, Raymond-Flesch M, Fernandes-Osterhold G, Bradley ER, O'Donovan A, Woolley J. PMID: 39823947.
      View in: PubMed   Mentions:
    2. Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials. JAMA Psychiatry. 2025 Jan 08. Matvey M, Kelley DP, Bradley ER, Chiong W, O'Donovan A, Woolley J. PMID: 39775830.
      View in: PubMed   Mentions:    Fields:    
    3. Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration. Am J Psychiatry. 2025 Jan 01; 182(1):17-20. Wolfgang AS, McClair VL, Schnurr PP, Holtzheimer PE, Woolley JD, Stauffer CS, Wolf RC, States LJ, Benedek DM, Capaldi VF, Bradley J, Fuller MA, Smyth MJ, Hermes EDA, Tenhula W, Wiechers IR. PMID: 39741441.
      View in: PubMed   Mentions:    Fields:    
    4. Maternal care is associated with neural and behavioral effects of oxytocin administration during empathic accuracy in schizophrenia and controls. Psychoneuroendocrinology. 2024 Nov 08; 172:107228. Brown CK, De Coster L, Lee J, Lin L, Mathalon DH, Woolley JD. PMID: 39581167.
      View in: PubMed   Mentions:    Fields:    
    5. Editorial: Down the rabbit hole - the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions. Front Psychiatry. 2024; 15:1431389. Peled-Avron L, Aday JS, Kalafateli AL, Hamilton HK, Woolley JD. PMID: 38915850; PMCID: PMC11194731.
      View in: PubMed   Mentions:
    6. Psychedelic-assisted psychotherapy: where is the psychotherapy research? Psychopharmacology (Berl). 2024 Aug; 241(8):1517-1526. Aday JS, Horton D, Fernandes-Osterhold G, O'Donovan A, Bradley ER, Rosen RC, Woolley JD. PMID: 38782821.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. Psychopharmacology (Berl). 2024 Aug; 241(8):1617-1630. Sakai K, Bradley ER, Zamaria JA, Agin-Liebes G, Kelley DP, Fish A, Martini V, Ferris MC, Morton E, Michalak EE, O'Donovan A, Woolley JD. PMID: 38687360.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    8. Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians. J Eat Disord. 2024 Apr 24; 12(1):49. Downey AE, Chaphekar AV, Woolley J, Raymond-Flesch M. PMID: 38659049; PMCID: PMC11040882.
      View in: PubMed   Mentions: 2  
    9. Quantifying abnormal emotion processing: A novel computational assessment method and application in schizophrenia. Psychiatry Res. 2024 Jun; 336:115893. Bradley ER, Portanova J, Woolley JD, Buck B, Painter IS, Hankin M, Xu W, Cohen T. PMID: 38657475.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study. J Psychoactive Drugs. 2024 Feb 04; 1-10. Aday JS, Bloesch EK, Davis AK, Domoff SE, Scherr K, Woolley JD, Davoli CC. PMID: 38310541.
      View in: PubMed   Mentions:    Fields:    
    11. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023 09 05; 330(9):843-853. Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR. PMID: 37651119; PMCID: PMC10472268.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    12. "But the reality is it's happening": A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy. Int J Eat Disord. 2023 Nov; 56(11):2142-2148. Downey AE, Boyd M, Chaphekar AV, Woolley J, Raymond-Flesch M. PMID: 37551650.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Reply to: Marketing pitches of 'magic mushrooms' and 'psychedelics' mask that psychotomimetics use exposes those vulnerable to serious adverse effects. J Psychopharmacol. 2023 07; 37(7):750-751. Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. PMID: 37439350.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Focus (Am Psychiatr Publ). 2023 Jul; 21(3):315-328. Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot'alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. PMID: 37404971; PMCID: PMC10316215.
      View in: PubMed   Mentions: 13  
    15. Emerging Challenges for Psychedelic Therapy. JAMA Psychiatry. 2023 06 01; 80(6):533-534. Aday JS, Carhart-Harris RL, Woolley JD. PMID: 37074690.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    16. Reply to: Marketing pitches of 'magic mushrooms' and 'psychedelics' mask that psychotomimetics use exposes those vulnerable to serious adverse effects. J Psychopharmacol. 2023 May 03; 2698811231169641. Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. PMID: 37132540.
      View in: PubMed   Mentions:    Fields:    
    17. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. J Psychopharmacol. 2023 01; 37(1):49-60. Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. PMID: 36515370; PMCID: PMC9834328.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    18. "A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. PLoS One. 2022; 17(12):e0279073. DellaCrosse M, Pleet M, Morton E, Ashtari A, Sakai K, Woolley J, Michalak E. PMID: 36516137; PMCID: PMC9749989.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. The effects of intranasal oxytocin on black participants' responses to outgroup acceptance and rejection. Front Psychol. 2022; 13:916305. Park J, Woolley J, Mendes WB. PMID: 36059785; PMCID: PMC9434127.
      View in: PubMed   Mentions: 2  
    20. Prior trauma exposure, posttraumatic stress symptoms, and COVID-19 vaccine hesitancy. J Psychiatr Res. 2022 07; 151:399-404. Nishimi K, Borsari B, Tripp P, Jiha A, Dolsen EA, Woolley JD, Neylan TC, O'Donovan A. PMID: 35588548; PMCID: PMC9096691.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    21. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl). 2022 Jun; 239(6):1989-2010. Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. PMID: 35359159; PMCID: PMC10184717.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    22. Posttraumatic stress disorder symptoms associated with protective and risky behaviors for coronavirus disease 2019. Health Psychol. 2022 Feb; 41(2):104-114. Nishimi K, Borsari B, Marx BP, Tripp P, Woodward E, Rosen RC, Cohen BE, Maven D, Jiha A, Woolley JD, Neylan TC, O'Donovan A. PMID: 35238581; PMCID: PMC8932400.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    23. Psilocybin for Trauma-Related Disorders. Curr Top Behav Neurosci. 2022; 56:319-332. Khan AJ, Bradley E, O'Donovan A, Woolley J. PMID: 35711024.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. Clusters of COVID-19 protective and risky behaviors and their associations with pandemic, socio-demographic, and mental health factors in the United States. Prev Med Rep. 2022 Feb; 25:101671. Nishimi K, Borsari B, Marx BP, Rosen RC, Cohen BE, Woodward E, Maven D, Tripp P, Jiha A, Woolley JD, Neylan TC, O'Donovan A. PMID: 34926133; PMCID: PMC8669937.
      View in: PubMed   Mentions: 8  
    25. Effects of oxytocin administration on fear-potentiated acoustic startle in co-occurring PTSD and alcohol use disorder: A randomized clinical trial. Psychiatry Res. 2022 02; 308:114340. Stauffer CS, Morrison TE, Meinzer NK, Leung D, Buffington J, Sheh EG, Neylan TC, O'Donovan A, Woolley JD. PMID: 34983010; PMCID: PMC9074818.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. Oxytocin increases physiological linkage during group therapy for methamphetamine use disorder: a randomized clinical trial. Sci Rep. 2021 10 25; 11(1):21004. Thorson KR, McKernan SM, West TV, Woolley JD, Mendes WB, Stauffer CS. PMID: 34697392; PMCID: PMC8546069.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    27. Analysis of Behavior Classification in Motivational Interviewing. Proc Conf. 2021 Jun; 2021:110-115. Tavabi L, Tran T, Stefanov K, Borsari B, Woolley JD, Scherer S, Soleymani M. PMID: 34337617; PMCID: PMC8321779.
      View in: PubMed   Mentions: 1  
    28. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 06; 27(6):1025-1033. Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot'alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. PMID: 33972795; PMCID: PMC8205851.
      View in: PubMed   Mentions: 247     Fields:    Translation:HumansCTClinical Trials
    29. Preliminary evidence that oxytocin does not improve mentalizing in women with schizophrenia. Horm Behav. 2021 02; 128:104915. Bradley ER, Tai M, Hankin M, Woolley JD. PMID: 33340522; PMCID: PMC7854492.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    30. Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience. ACS Pharmacol Transl Sci. 2021 Apr 09; 4(2):526-532. Stauffer CS, Anderson BT, Ortigo KM, Woolley J. PMID: 33860182; PMCID: PMC8033604.
      View in: PubMed   Mentions: 23  
    31. Multimodal Automatic Coding of Client Behavior in Motivational Interviewing. Proc ACM Int Conf Multimodal Interact. 2020 Oct; 2020:406-413. Tavabi L, Borsari B, Stefanov K, Woolley JD, Soleymani M, Zhang L, Scherer S. PMID: 34337616; PMCID: PMC8321780.
      View in: PubMed   Mentions: 3  
    32. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020 Oct; 27:100538. Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, Trope A, Boden MT, Dilley PJ, Mitchell J, Woolley J. PMID: 33150319; PMCID: PMC7599297.
      View in: PubMed   Mentions: 57  
    33. Oxytocin does not improve emotional prosody recognition in schizophrenia-spectrum disorders. Compr Psychoneuroendocrinol. 2020 Nov; 4:100011. Chuang BJ, Campellone TR, Woolley JD. PMID: 35755629; PMCID: PMC9216402.
      View in: PubMed   Mentions:
    34. Automatic Imitation in Comorbid PTSD & Alcohol Use Disorder and Controls: an RCT of Intranasal Oxytocin. Psychoneuroendocrinology. 2020 10; 120:104787. Morrison TE, De Coster L, Stauffer CS, Wen J, Ahmadi E, Delucchi K, O'Donovan A, Woolley J. PMID: 32745891; PMCID: PMC7502459.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Enhancing prolonged exposure therapy for PTSD among veterans with oxytocin: Design of a multisite randomized controlled trial. Contemp Clin Trials. 2020 08; 95:106074. Flanagan JC, Mitchell JM, Baker NL, Woolley J, Wangelin B, Back SE, McQuaid JR, Neylan TC, Wolfe WR, Brady KT. PMID: 32561468; PMCID: PMC7484278.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    36. Oxytocin-enhanced group therapy for methamphetamine use disorder: Randomized controlled trial. J Subst Abuse Treat. 2020 09; 116:108059. Stauffer CS, Moschetto JM, McKernan S, Meinzer N, Chiang C, Rapier R, Hsiang E, Norona J, Borsari B, Woolley JD. PMID: 32741502; PMCID: PMC7491413.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    37. Social integration and inflammation in individuals with and without posttraumatic stress disorder. Brain Behav Immun. 2020 10; 89:168-174. Ahmadian AJ, Lin JE, Neylan TC, Woolley JD, O'Donovan A, Cohen BE. PMID: 32534985; PMCID: PMC8388310.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    38. Randomized Controlled Trial Testing Mobile-Based Attention-Bias Modification for Posttraumatic Stress Using Personalized Word Stimuli. Clin Psychol Sci. 2020 Jul; 8(4):756-772. Niles AN, Woolley JD, Tripp P, Pesquita A, Vinogradov S, Neylan TC, O'Donovan A. PMID: 34414018; PMCID: PMC8373050.
      View in: PubMed   Mentions: 10  
    39. Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial. Schizophr Bull. 2020 04 10; 46(3):661-669. Abram SV, De Coster L, Roach BJ, Mueller BA, van Erp TGM, Calhoun VD, Preda A, Lim KO, Turner JA, Ford JM, Mathalon DH, Woolley JD. PMID: 31595302; PMCID: PMC7147578.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    40. Six month durability of targeted cognitive training supplemented with social cognition exercises in schizophrenia. Schizophr Res Cogn. 2020 Jun; 20:100171. Miley K, Fisher M, Nahum M, Howard E, Rowlands A, Brandrett B, Woolley J, Hooker CI, Biagianti B, Ramsay I, Vinogradov S. PMID: 31908976; PMCID: PMC6938953.
      View in: PubMed   Mentions: 20  
    41. Effects of Oxytocin Administration on Cue-Induced Craving in Co-occurring Alcohol Use Disorder and PTSD: A Within-Participant Randomized Clinical Trial. Alcohol Clin Exp Res. 2019 12; 43(12):2627-2636. Stauffer CS, Meinzer NK, Morrison T, Wen JH, Radanovich L, Leung D, Niles A, O'Donovan A, Batki SL, Woolley JD. PMID: 31610033; PMCID: PMC7450809.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    42. Oxytocin increases eye gaze in schizophrenia. Schizophr Res. 2019 10; 212:177-185. Bradley ER, Seitz A, Niles AN, Rankin KP, Mathalon DH, O'Donovan A, Woolley JD. PMID: 31416746; PMCID: PMC6791758.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    43. Neural and behavioral effects of oxytocin administration during theory of mind in schizophrenia and controls: a randomized control trial. Neuropsychopharmacology. 2019 10; 44(11):1925-1931. De Coster L, Lin L, Mathalon DH, Woolley JD. PMID: 31103018; PMCID: PMC6785003.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    44. Psychedelic-Assisted Group Therapy: A Systematic Review. J Psychoactive Drugs. 2019 Apr-Jun; 51(2):174-188. Trope A, Anderson BT, Hooker AR, Glick G, Stauffer C, Woolley JD. PMID: 30950777; PMCID: PMC6650145.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    45. Victory is its own reward: oxytocin increases costly competitive behavior in schizophrenia. Psychol Med. 2020 03; 50(4):674-682. Bradley ER, Brustkern J, De Coster L, van den Bos W, McClure SM, Seitz A, Woolley JD. PMID: 30944045.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    46. Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity. Biol Psychiatry. 2019 06 15; 85(12):e75-e76. Marton T, Barnes DE, Wallace A, Woolley JD. PMID: 30926131.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    47. Oxytocin-enhanced motivational interviewing group therapy for methamphetamine use disorder in men who have sex with men: study protocol for a randomized controlled trial. Trials. 2019 Feb 21; 20(1):145. Stauffer CS, Moschetto JM, McKernan SM, Hsiang E, Borsari B, Woolley JD. PMID: 30791944; PMCID: PMC6385415.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    48. Oxytocin does not improve working memory in schizophrenia. Schizophr Res. 2019 06; 208:486-487. Bradley ER, van Nieuwenhuizen A, Abram S, Niles AN, Woolley JD. PMID: 30712813; PMCID: PMC7297462.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    49. Social motivation in schizophrenia: The impact of oxytocin on vigor in the context of social and nonsocial reinforcement. J Abnorm Psychol. 2018 01; 127(1):116-128. Fulford D, Treadway M, Woolley J. PMID: 29369669; PMCID: PMC7446385.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    50. Effects of oxytocin administration on receiving help. Emotion. 2018 Oct; 18(7):980-988. Human LJ, Woolley JD, Mendes WB. PMID: 29172621.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Intranasal Oxytocin May Improve High-Level Social Cognition in Schizophrenia, But Not Social Cognition or Neurocognition in General: A Multilevel Bayesian Meta-analysis. Schizophr Bull. 2017 10 21; 43(6):1291-1303. Bürkner PC, Williams DR, Simmons TC, Woolley JD. PMID: 28586471; PMCID: PMC5737621.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    52. Feasibility and preliminary efficacy of remotely delivering cognitive training to people with schizophrenia using tablets. Schizophr Res Cogn. 2017 Dec; 10:7-14. Biagianti B, Fisher M, Howard L, Rowlands A, Vinogradov S, Woolley J. PMID: 28824850; PMCID: PMC5544490.
      View in: PubMed   Mentions: 12  
    53. Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward. Neurosci Biobehav Rev. 2017 Sep; 80:36-56. Bradley ER, Woolley JD. PMID: 28506922; PMCID: PMC5682229.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    54. Combining oxytocin administration and positive emotion inductions: Examining social perception and analytical performance. Horm Behav. 2017 04; 90:120-128. Human LJ, Thorson KR, Woolley JD, Mendes WB. PMID: 28324706.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Supplementing intensive targeted computerized cognitive training with social cognitive exercises for people with schizophrenia: An interim report. Psychiatr Rehabil J. 2017 03; 40(1):21-32. Fisher M, Nahum M, Howard E, Rowlands A, Brandrett B, Kermott A, Woolley J, Vinogradov S. PMID: 28368179; PMCID: PMC5380146.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    56. Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls. Psychol Med. 2017 May; 47(7):1311-1322. Woolley JD, Chuang B, Fussell C, Scherer S, Biagianti B, Fulford D, Mathalon DH, Vinogradov S. PMID: 28091349; PMCID: PMC6939989.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    57. Creating Live Interactions to Mitigate Barriers (CLIMB): A Mobile Intervention to Improve Social Functioning in People With Chronic Psychotic Disorders. JMIR Ment Health. 2016 Dec 13; 3(4):e52. Biagianti B, Schlosser D, Nahum M, Woolley J, Vinogradov S. PMID: 27965190; PMCID: PMC5192235.
      View in: PubMed   Mentions: 22     Fields:    
    58. The impact of CACNA1C gene, and its epistasis with ZNF804A, on white matter microstructure in health, schizophrenia and bipolar disorder1. Genes Brain Behav. 2017 04; 16(4):479-488. Mallas E, Carletti F, Chaddock CA, Shergill S, Woolley J, Picchioni MM, McDonald C, Toulopoulou T, Kravariti E, Kalidindi S, Bramon E, Murray R, Barker GJ, Prata DP. PMID: 27790829.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    59. American Alcohol Photo Stimuli (AAPS): A standardized set of alcohol and matched non-alcohol images. Am J Drug Alcohol Abuse. 2017 11; 43(6):647-655. Stauffer CS, Dobberteen L, Woolley JD. PMID: 27893279; PMCID: PMC7457470.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    60. A two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder. Addict Res Theory. 2016; 24(6):490-498. Stauffer CS, Musinipally V, Suen A, Lynch KL, Shapiro B, Woolley JD. PMID: 28503120; PMCID: PMC5424696.
      View in: PubMed   Mentions: 23  
    61. The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study. Psychopharmacology (Berl). 2016 07; 233(13):2571-80. Woolley JD, Arcuni PA, Stauffer CS, Fulford D, Carson DS, Batki S, Vinogradov S. PMID: 27137199; PMCID: PMC7452038.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    62. Intranasal Oxytocin Selectively Modulates Social Perception, Craving, and Approach Behavior in Subjects With Alcohol Use Disorder. J Addict Med. 2016 May-Jun; 10(3):182-9. Mitchell JM, Arcuni PA, Weinstein D, Woolley JD. PMID: 27159342.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    63. Intranasal Oxytocin Mechanisms Can Be Better Understood, but Its Effects on Social Cognition and Behavior Are Not to Be Sniffed At. Biol Psychiatry. 2016 Apr 15; 79(8):e49-50. Quintana DS, Woolley JD. PMID: 26212900.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    64. Impaired Recognition and Regulation of Disgust Is Associated with Distinct but Partially Overlapping Patterns of Decreased Gray Matter Volume in the Ventroanterior Insula. Biol Psychiatry. 2015 Oct 01; 78(7):505-14. Woolley JD, Strobl EV, Sturm VE, Shany-Ur T, Poorzand P, Grossman S, Nguyen L, Eckart JA, Levenson RW, Seeley WW, Miller BL, Rankin KP. PMID: 25890642; PMCID: PMC4529378.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    65. Oxytocin administration selectively improves olfactory detection thresholds for lyral in patients with schizophrenia. Psychoneuroendocrinology. 2015 Mar; 53:217-22. Woolley JD, Lam O, Chuang B, Ford JM, Mathalon DH, Vinogradov S. PMID: 25637811; PMCID: PMC4503321.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    66. Can we bottle psychosocial treatments for addiction? The role of oxytocin. J Clin Psychiatry. 2014 Sep; 75(9):1028-9. Stauffer CS, Woolley JD. PMID: 25295428; PMCID: PMC7448555.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    67. Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology. 2014 Sep; 47:116-25. Woolley JD, Chuang B, Lam O, Lai W, O'Donovan A, Rankin KP, Mathalon DH, Vinogradov S. PMID: 25001961; PMCID: PMC4280262.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    68. Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. Psychol Med. 2014 Dec; 44(16):3491-501. Modinos G, Allen P, Frascarelli M, Tognin S, Valmaggia L, Xenaki L, Keedwell P, Broome M, Valli I, Woolley J, Stone JM, Mechelli A, Phillips ML, McGuire P, Fusar-Poli P. PMID: 25066827.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    69. Satiety-related hormonal dysregulation in behavioral variant frontotemporal dementia. Neurology. 2014 Feb 11; 82(6):512-20. Woolley JD, Khan BK, Natesan A, Karydas A, Dallman M, Havel P, Miller BL, Rankin KP. PMID: 24415571; PMCID: PMC3937860.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    70. A new biomarker of hedonic eating? A preliminary investigation of cortisol and nausea responses to acute opioid blockade. Appetite. 2014 Mar; 74:92-100. Daubenmier J, Lustig RH, Hecht FM, Kristeller J, Woolley J, Adam T, Dallman M, Epel E. PMID: 24291355; PMCID: PMC4125886.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    71. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014 Feb; 44(3):499-506. Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, Rahaman N, Joyce J, Hinton M, Johnson S, Young AH, MiData Consortium. PMID: 23701858.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    72. Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis. Psychol Med. 2014 Feb; 44(3):489-98. Tognin S, Riecher-Rössler A, Meisenzahl EM, Wood SJ, Hutton C, Borgwardt SJ, Koutsouleris N, Yung AR, Allen P, Phillips LJ, McGorry PD, Valli I, Velakoulis D, Nelson B, Woolley J, Pantelis C, McGuire P, Mechelli A. PMID: 23659473; PMCID: PMC3880065.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    73. BDNF serum concentrations show no relationship with diagnostic group or medication status in neurodegenerative disease. Curr Alzheimer Res. 2012 Sep; 9(7):815-21. Woolley JD, Strobl EV, Shelly WB, Karydas AM, Robin Ketelle RN, Wolkowitz OM, Miller BL, Rankin KP. PMID: 21605064; PMCID: PMC3176995.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    74. Schizophrenia or neurodegenerative disease prodrome? Outcome of a first psychotic episode in a 35-year-old woman. Psychosomatics. 2012 May-Jun; 53(3):280-4. Khan BK, Woolley JD, Chao S, See T, Karydas AM, Miller BL, Rankin KP. PMID: 22284422; PMCID: PMC3660996.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    75. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011 Feb; 72(2):126-33. Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. PMID: 21382304; PMCID: PMC3076589.
      View in: PubMed   Mentions: 174     Fields:    Translation:Humans
    76. Neuromyelitis optica, psychiatric symptoms and primary polydipsia: a case report. Gen Hosp Psychiatry. 2010 Nov-Dec; 32(6):648.e5-8. Woolley J, Douglas VC, Cree BA. PMID: 21112466.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    77. Frontotemporal dementia and mania. Am J Psychiatry. 2007 Dec; 164(12):1811-6. Woolley JD, Wilson MR, Hung E, Gorno-Tempini ML, Miller BL, Shim J. PMID: 18056235.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    78. Binge eating is associated with right orbitofrontal-insular-striatal atrophy in frontotemporal dementia. Neurology. 2007 Oct 02; 69(14):1424-33. Woolley JD, Gorno-Tempini ML, Seeley WW, Rankin K, Lee SS, Matthews BR, Miller BL. PMID: 17909155.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    79. Opposing effects of intra-nucleus accumbens mu and kappa opioid agonists on sensory specific satiety. Neuroscience. 2007 Jun 08; 146(4):1445-52. Woolley JD, Lee BS, Kim B, Fields HL. PMID: 17445988.
      View in: PubMed   Mentions: 15     Fields:    Translation:Animals
    80. Nucleus accumbens opioid signaling conditions short-term flavor preferences. Neuroscience. 2007 Apr 25; 146(1):19-30. Woolley JD, Lee BS, Taha SA, Fields HL. PMID: 17320293.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    81. Nucleus accumbens opioids regulate flavor-based preferences in food consumption. Neuroscience. 2006 Nov 17; 143(1):309-17. Woolley JD, Lee BS, Fields HL. PMID: 17049180.
      View in: PubMed   Mentions: 34     Fields:    Translation:Animals
    82. Endogenous opioids encode relative taste preference. Eur J Neurosci. 2006 Aug; 24(4):1220-6. Taha SA, Norsted E, Lee LS, Lang PD, Lee BS, Woolley JD, Fields HL. PMID: 16925586.
      View in: PubMed   Mentions: 17  Translation:AnimalsCells
    83. The autonomic and behavioral profile of emotional dysregulation. Neurology. 2004 Nov 09; 63(9):1740-3. Woolley JD, Gorno-Tempini ML, Werner K, Rankin KP, Ekman P, Levenson RW, Miller BL. PMID: 15534273.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. Cognitive and behavioral profile in a case of right anterior temporal lobe neurodegeneration. Cortex. 2004 Sep-Dec; 40(4-5):631-44. Gorno-Tempini ML, Rankin KP, Woolley JD, Rosen HJ, Phengrasamy L, Miller BL. PMID: 15505973.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    85. Buccofacial apraxia and the expression of emotion. Ann N Y Acad Sci. 2003 Dec; 1000:395-401. Woolley JD. PMID: 14766655.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    86. From simple desires to ordinary beliefs: the early development of everyday psychology. Cognition. 1990 Jun; 35(3):245-75. Wellman HM, Woolley JD. PMID: 2364653.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    Joshua's Networks
    Concepts (272)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (55)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-8-gc1ed69da on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.